SUIT-015: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
|abbr=FNS(Oct,PGM) | |abbr=FNS(Oct,PGM) | ||
|description=[[File:1OctM;2D;3G;4P;5S;6U;7Rot-.png|300px]] | |description=[[File:1OctM;2D;3G;4P;5S;6U;7Rot-.png|300px]] | ||
|info=''' | |info='''B''' [[Schoepf 2016 FEBS J]] | ||
|application=O2 | |application=O2 | ||
}} | }} | ||
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PGM) | ::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PGM) | ||
::: '''[[SUIT protocol pattern]]:''' diametral 1OctM;2D;3G;4P;5S;6U;7Rot | ::: '''[[SUIT protocol pattern]]:''' diametral 1OctM;2D;3G;4P;5S;6U;7Rot | ||
Line 50: | Line 42: | ||
== Compare SUIT protocols == | == Compare SUIT protocols == | ||
Β Β | Β Β | ||
::::* [[SUIT-002]] | |||
::::* [[1PalM;2D;3Oct;4P;5G;6U;7S;8Rot-]] 1PalM;2D;3Oct;4P;5G;6U;7S;8Rot- | ::::* [[1PalM;2D;3Oct;4P;5G;6U;7S;8Rot-]] 1PalM;2D;3Oct;4P;5G;6U;7S;8Rot- | ||
::::* [[1PGM;2D;3S;4U;5Rot-]] 1PGM;2D;3S;4U;5Rot- | ::::* [[1PGM;2D;3S;4U;5Rot-]] 1PGM;2D;3S;4U;5Rot- | ||
Line 57: | Line 50: | ||
{{MitoPedia concepts | {{MitoPedia concepts | ||
|mitopedia concept=SUIT | |mitopedia concept=SUIT B | ||
}} | |||
{{MitoPedia methods | |||
|mitopedia method=Respirometry | |||
}} | }} |
Revision as of 11:21, 15 January 2019
Description
Abbreviation: FNS(Oct,PGM)
Reference: B Schoepf 2016 FEBS J
O2k-Application: O2
- SUIT-category: FNS(Oct,PGM)
- SUIT protocol pattern: diametral 1OctM;2D;3G;4P;5S;6U;7Rot
References
Year | Reference | Organism | Tissue;cell | |
---|---|---|---|---|
Schoepf 2016 FEBS J | 2016 | SchΓΆpf B, SchΓ€fer G, Weber A, Talasz H, Eder IE, Klocker H, Gnaiger E (2016) Oxidative phosphorylation and mitochondrial function differ between human prostate tissue and cultured cells. https://doi.org/10.1111/febs.13733 | Human | Endothelial;epithelial;mesothelial cell Genital Other cell lines Fibroblast |
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML | F(N) | CETF | 1OctM
|
2D | OctMP | F(N) | CETF | 1OctM;2D
|
3G | OctGMP | FN | CETF&CI | 1OctM;2D;3G
|
3c | OctGMcP | FN | CETF&CI | 1OctM;2D;3G;3c
|
4P | OctPGMP | FN | CETF&CI | 1OctM;2D;3G;3c;4P
|
5S | OctPGMSP | FNS | CETF&CI&II | 1OctM;2D;3G;3c;4P;5S
|
6U | OctPGMSE | FNS | CETF&CI&II | 1OctM;2D;3G;3c;4P;5S;6U
|
7Rot | SE | S | CII | 1OctM;2D;3G;3c;4P;5S;6U;7Rot
|
8Ama | ROX | 1OctM;2D;3G;3c;4P;5S;6U;7Rot;8Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- Β» Electron transfer pathway
- Β» Fatty acid oxidation pathway control state, F
- Β» NADH electron transfer-pathway state, N
- Β» Succinate pathway control state, S
- Β» NS-pathway control state, NS
- Β» Glycerophosphate pathway control state, Gp
- Β» Complex IV single step, CIV
- Β» Anaplerotic pathway control state
- Pathway control
- Main fuel substrates
- Β» Glutamate, G
- Β» Glycerophosphate, Gp
- Β» Malate, M
- Β» Octanoylcarnitine, Oct
- Β» Pyruvate, P
- Β» Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- + The protocol provides information on FAO capacity in the absence of other, potentially interfering pathways, both in the LEAK state and in OXPHOS.
- + FNS OXPHOS capacity comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
- + FNS ET capacity is a good estimate of overal ET capacity in may cell types.
- + The presence of PMG and S establishes fully operative TCA cycle activity.
- + Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- + Reasonable duration of the experiment.
- - F OXPHOS capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemuieux et al 2011).
- - SRot(E) may be underestimated if S is not saturating.
- - CIV activity is not measured, to save experimental time.
Compare SUIT protocols
- SUIT-002
- 1PalM;2D;3Oct;4P;5G;6U;7S;8Rot- 1PalM;2D;3Oct;4P;5G;6U;7S;8Rot-
- 1PGM;2D;3S;4U;5Rot- 1PGM;2D;3S;4U;5Rot-
1PalM;2D;3Oct;4P;5G;6U;7S;8Rot
MitoPedia concepts: SUIT B
MitoPedia methods:
Respirometry